非小细胞肺癌免疫治疗之假性进展和超进展

Pseudoprogressive and Hyperprogressive Disease in Non-small Cell Lung Cancer Patients with Immunotherapy

随着医疗技术日益发展,肿瘤治疗取得了显著的进步。其中,免疫治疗为肺癌患者开辟了一条全新的道路,其代表药物——PD-1/PD-L1抑制剂的应用显著延长了部分非小细胞肺癌(NSCLC)患者的整体生存率,但在使用过程中也可能出现假性进展或超进展(HPD)现象,其发生机制尚未明确。本文将对假性进展和HPD的定义、发生机制以及可供参考的生物标志物及鉴别方法进行系统地综述。

With the development of medical technology,cancer treatment has made significant progress.Immunotherapy has opened up a new road for lung cancer patients.Among them,PD-1/PD-L1 inhibitors,become the representative drugs.Their applications have significantly extended the overall survival rate of some non-small cell lung cancer(NSCLC)patients.However,pseudoprogression or hyperprogressive disease(HPD)may occur in the process of treatment,and the mechanism of such phenomena remains unclear.In this article,we systematically reviewed their definitions,mechanisms,and predictive biomarkers and identification for reference.